What is the specific mechanism of action of niraparibabiraterone tablets?

Niraparib, abiraterone tablets (Akeega) is a compound oral preparation composed of two targeted drugs, specially designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutation background. Its innovation lies in acting on two key tumor signaling pathways at the same time, thereby achieving stronger anti-cancer effects and extending disease control time. Specifically, Akeega's mechanism is to destroy the core survival pathways of tumor cells through a dual-targeting strategy of PARP inhibition + androgen synthesis inhibition.

Niraparib, as a highly selectivePARP inhibitor (Poly ADP-ribose polymerase inhibitor), can block the ability of tumor cells to repair DNA damage. BRCA1/2 mutated tumor cells have lost part of their DNA double-strand repair ability, and PARP further inhibits the single-strand repair pathway, causing the cells to fall into a "synthetic lethal" state, thereby achieving precise killing. This mechanism is particularly effective for BRCA mutation subtypes in prostate cancer and can significantly improve therapeutic targeting.

Abiraterone is aCYP17 enzyme inhibitor that blocks the synthesis of testosterone and other androgens, thereby further inhibiting the hormone-dependent growth of prostate cancer cells. Abiraterone can act simultaneously within the testicles, adrenal glands, and tumor tissues, giving it broader coverage than traditional androgen deprivation therapy. Therefore, its combination with niraparib creates a synergistic effect, which not only interferes with the hormone signaling dependence of tumors, but also disrupts its drug resistance mechanism from the DNA repair level.

As a fixed-dose combination preparation, Akeega is convenient for once-daily dosing, and is designed to balance the pharmacokinetic parameters between the two drugs to ensure synchronized effects in the body. This combined mechanism is particularly suitable for mCRPC patients with DNA repair deficiency background. It can not only delay tumor progression, but also have the potential to extend survival. It is one of the representative "dual-channel" solutions in current precision therapy.

Reference materials:https://www.drugs.com/akeega.html